Search clinical trials for: Polypure 22S hemodialyzer

Total 761 results

Hemotech

Completed

Evaluation of Biocompatibility and Performances of 4 Dialyzers in Different Mode Treatments (BIOMODAL)

Inflammation | End Stage Renal Disease

France
Medtronic - MITG

Completed

Clearum High Flux Hemodialyzer Used in Hemodialysis for Subjects With End-Stage Renal Disease

End-stage Renal Disease

Germany
University Hospital, Ghent

Completed

Anticoagulation in Chronic Hemodialysis Patients Versus Hemodialyzer Fiber Patency, Bleedings and Quality of Life (ClotSigns)

Blood Coagulation

Belgium
University Hospital, Ghent

Active, not recruiting

Dialysis Performance of the FX CorAL Membrane (PATENCY)

Hemodialysis Complication | Anticoagulants

Belgium
University Hospital, Ghent
University Ghent

Completed

Optimisation of Anticoagulation in Patients on Nocturnal Hemodialysis

Hemodialysis | Coagulation

Belgium
National Taiwan University Hospital
Mrs. Hsiu-Chin Lee Kidney Research Fund

Unknown

High Flux Hemodialysis Thrice Versus Once

End-Stage Renal Disease

Taiwan
Iperboreal Pharma Srl

Not yet recruiting

Peritoneal Ultrafiltration in Cardio Renal Syndrome. (PURE)

Congestive Heart Failure

Italy
City of Hope Medical Center
Addario Lung Cancer Medical Institute

Withdrawn

ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Carcinoma

United States
Baxter Healthcare Corporation
Gambro Lundia AB

Completed

Reduction of Heparin Dose in Dialysis With Evodial System (RHODES)

Chronic Kidney Failure

Sweden, France, Germany, Italy
Celgene

Completed

A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers

Neoplasms

United States, France, Italy, Poland, Spain, United Kingdom
Global Alliance for TB Drug Development

Completed

Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

Tuberculosis | Tuberculosis, Pulmonary

United States
Celgene

Completed

2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects

Healthy

United States
Nguyen Thi Trieu, MD

Completed

Prevention and Treatment of Patient Before, During, and After Covid-19 Infection (AntiCov-220)

Covid19

Vietnam
Global Alliance for TB Drug Development

Completed

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults

Tuberculosis | Tuberculosis, Pulmonary

United States
MediciNova

Completed

Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
Therapex Co., Ltd

Not yet recruiting

A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients

Carcinoma, Non-Small-Cell Lung | EGFR Mutant Advanced Non-Small Cell Lung Cancer
Hao Feng

Enrolling by invitation

The Role and Mechanism of GPER-Hippo-CBS/H2S Pathway in Preeclampsia

Preeclampsia

China
Takeda

Completed

A Study of TAK-227 in Healthy Adults

Healthy Volunteers

United States
Calithera Biosciences, Inc

Terminated

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies

Advanced Nonhematological Neoplasms

Korea, Republic of, Japan, Taiwan
Rubius Therapeutics

Terminated

RTX-224 Monotherapy in Patients With Solid Tumors

Non Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Cutaneous Melanoma | TNBC - Triple-Negative Breast Cancer

United States
Amgen

Terminated

Safety Study of AMG 228 to Treat Solid Tumors

Melanoma | Cancer | Colorectal Cancer | Advanced Solid Tumors | Squamous Cell Carcinoma of the Head and Neck | Non-small Cell Lung Cancer | Oncology | Tumors | Advanced Malignancy | Oncology Patients | Transitional Cell Carinoma of Bladder

Belgium, France, United States, Germany, Australia
Celgene

Completed

A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects

Healthy Volunteers

United States
MedImmune LLC
GlaxoSmithKline

Completed

Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer

Cancer

United States
Celgene

Completed

Radiolabeled Study of AG-221 in Healthy Male Subjects.

Healthy Volunteers
Celgene

Withdrawn

A Phase 2 Study With CC-220 in Skin Sarcoidosis

Sarcoidosis
AdventHealth

Completed

22G FNA Needle vs. 22G ProCore Needle

Pancreatic Neoplasm

United States
M.D. Anderson Cancer Center
Bayer; Prostate Cancer Foundation

Completed

Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases

Prostate Cancer

United States
AbbVie

Recruiting

A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult Participants

Facial Volume Deficit

Germany, Spain
Peel Therapeutics Inc

Recruiting

A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
UBP Greater China (Shanghai) Co., Ltd

Not yet recruiting

Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of UB-221 in Healthy Volunteers

Chronic Spontaneous Urticaria
Celgene

Completed

Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects

Healthy Volunteers | Hepatic Impairment

United States
Celgene

Completed

PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian Subjects

Healthy

United States
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Recruiting

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

Churg-Strauss Syndrome | Eosinophilic Granulomatosis With Polyangiitis

United States, Japan
Celgene

Completed

Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function

Renal Insufficiency

United States
Celgene

Completed

A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.

Systemic Lupus Erythematosus

United States
University of Southern California
National Cancer Institute (NCI)

Active, not recruiting

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer | Prostate Carcinoma Metastatic in the Bone

United States
University of Washington
Bayer

Recruiting

Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8

United States
POINT Biopharma, a wholly owned subsidiary of Eli...
Eli Lilly and Company

Recruiting

[Ac-225]-PSMA-62 Trial in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer (ACCEL)

Prostate Cancer | Biochemically Recurrent Prostate Carcinoma | Metastatic Castration-resistant Prostate Cancer

Canada
Celgene

Completed

Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States
Inter-American Development Bank
Universidade Federal do Ceara; Municipal Secretary of Health, Fortaleza Brasil

Unknown

Evaluation of the Home Visiting Pilot Program on Early Childhood Outcomes in Fortaleza Brazil

Child Development
Ferrer Internacional S.A.

Not yet recruiting

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy
Bradley A. McGregor, MD
Calithera Biosciences, Inc

Completed

Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma

United States
Groupe Francophone des Myelodysplasies

Active, not recruiting

IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia Acute Myeloid

France
Radboud University Medical Center
Bayer

Completed

Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic CRPC Patients Treated With Radium-223

Bone Metastases | Castrate Resistant Prostate Cancer

Netherlands
Celgene Corporation

Completed

3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule

Healthy Volunteers

United States
MediciNova

Completed

Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma

Asthma

United States
Celgene

Completed

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Belgium, Germany, Spain, Canada, Serbia, Colombia, Poland, Argentina, Brazil, Mexico, Hungary, France, Russian Federation, Italy
Calithera Biosciences, Inc

Terminated

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Squamous Non-small-cell Lung Cancer | NFE2L2 Gene Mutation | Squamous Non-Small Cell Neoplasm of Lung

United States
Amgen

Completed

Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia

End Stage Renal Disease | Chronic Kidney Disease | Kidney Disease | Hyperphosphatemic
Vertex Pharmaceuticals Incorporated

Completed

Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects

Hepatitis C

New Zealand

Search clinical trials for: Polypure 22S hemodialyzer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations